Chong Kun Dang faces Hanmi due to Rivaroxaban 2.5mg

Hanmi preoccupy generic (2.5mg) market alone by acquiring generic for exclusivity

Chong Kun Dang capsule formulation avoids generic for exclusivity, and patents seem to have been resolved

Riroxia 10mg, which was released five months before the expiration of the original material patent by Chong Kun Dang, dominated the generic market.

 

Next month, capsule-type 2.5mg products will be listed, and it is expected to face off with Hanmi over the generic market

Chong Kun Dang anticoagulant Rivaroxaban 2.5mg will be listed as the second generic drug after Hanmi.

 

Since Chong Kun Dang has shown extraordinary affection for anti-coagulation oral new drugs, it is expected that it will also focus its efforts on low dose Rivaroxaban products.

 

According to the industry on the 22nd, Riroxia capsules 2.5mg will be listed next month.

 

The original Rivaroxaban product is Bayer's Xarelto.

 

However, 2.5mg product could not be released because it still has a patent for its product and a patent for its use, and Hanmi Pharmaceutical and SK Chemical acquired generic for exclusivity.

 

There is also a difference in adaptation of the low dose (2.5 mg) and other doses.

 

If 10, 15, and 20 mg are also used for treatment such as treatment of cardiac venous thrombosis and pulmonary embolism, 2.5 mg prodcut is used for the prevention of cardiovascular disease like aspirin.

 

Studies show that using Xarelto 2.5 mg with Aspirin relatively reduced the risk of death from stroke, myocardial infarction, and cardiovascular disease in adult patients with coronary artery disease or symptoms than Aspirin alone.

 

Accordingly, Bayer, which owns Xarelto, also paid more attention to generic blocking than other doses, such as registering 2.5 mg patent and use patent separately in Korea.

 

Hanmi Pharmaceutical and SK Chemical succeeded in invalidating and avoiding 2.5mg of patents, respectively, and through this, they obtained generic for exclusivity.

 

When the material patent was terminated in October last year, other pharmaceutical companies were not able to release 2.5mg products, but Hanmi, which acquired generic for exclusivity, was able to release the product.

 

Currently, Original Bayer and Hanmi Pharmaceutical are the only pharmaceutical companies that have registered Rivaroxaban 2.5mg products.

 

Chong Kun Dang could have been released in October last year if it had solved the original patent.

 

Chong Kun Dang products are capsule formulations and are different from those of Korea.

 

It seems that the registration was belatedly promoted because the patent for use was still in existence at the time.

 

Currently, the Korean Supreme Court has ruled that the patent is invalid due to the request from Hanmi, and the final registration is about to be invalidated.

 

The patent for use also expires on the 7th of next month.

 

Although Chong Kun Dang belatedly releases 2.5mg products, they are faster than other post-refining drugs.

 

This is because Rivaroxaban 2.5mg tablets can be released only on July 4 when the generic for exclusivity period between Hanmi and SK ends.

 

Chong Kun Dang is working harder than any other pharmaceutical company in Korea on anticoagulant oral medicine generics.

 

Rivaroxaban's other products, excluding 2.5 mg, also reduced some of the indications related to prolongation of life and pushed ahead with the launch five months before the expiration of the material patent.

 

Chong Kun Dang requested a trial to confirm the scope of rights to avoid material patents.

 

The request for the trial was dismissed in July last year, and Chong Kun Dang appealed to the Patent Court.

 

However, Chong Kun Dang explained that Bayer's application for an injunction against patent infringement requested by the Seoul Central District Court has been rejected based on the judgment that it does not infringe material patents due to reduced indications.

 

Chong Kun Dang ranks first in the Rivaroxaban market.

 

Chong Kun Dang is conducting marketing under the plan to expand the original anticoagulant drugs to local clinics as they remain only in prescriptions for hospitals.

 

Riroxia 2.5mg, which is listed at this time, is also expected to launch a large-scale marketing by Chong Kun Dang.

 

It is expected that they will make desperate efforts to fight against Hanmi, which dominated the late drug market.

 

The drug price was also set at 700 won, the same as 2.5 mg of Riroxban in Korea and Hanmi.

 

As it is a showdown between the Chong Kun Dang, which has the strongest sales power in Clinics, and Hanmi, fierce competition is expected.